Low back pain due to lumbar Degenerative Disc Disease (DDD) is one of the most common causes of disability and morbidity, particularly among older adults. Current research efforts in lumbar DDD management are shifting towards identifying and correcting the pathology in intervertebral discs without any external manipulation. Herein, we present a systematic review of current literature regarding regenerative treatments for lumbar DDD. An electronic search of databases including PubMed, Ovid/MEDLINE, Cochrane and Scopus was conducted for articles in all available years. Studies that investigated treatment for discogenic pain in lumbar DDD, including any type of stem cell or bone marrow concentrate as the treatment agent and studies that report both baseline and follow-up pain and Oswestry Disability Index (ODI) scores were included in the review. Changes in pain and ODI scores were calculated for 3-month, 6-month and 12-month periods. Six studies with a total of 93 patients were evaluated. Mean (SD) age of the pooled sample was 40.0(8.1) and 39.5% (32/81) of patients were female. Pain improvement was reported in 38.8% of patients at 3-month, 40.8% at 6-month and 44.1% at 12-month follow-up. Average improvement in ODI score for 3-month, 6-month and 12-month follow-ups was calculated to be 24.0, 26.5 and 25.7, respectively. Regenerative treatments are being increasingly employed across all spectrums of medicine. Review of six single arm studies revealed a potential positive impact in the preliminary results. However, these promising 'preliminary' results should not be interpreted as the definite treatment and should be validated with further prospective studies.

中文翻译：

---

再生疗法在腰椎间盘突出症治疗中的应用：系统评价

腰椎退行性椎间盘疾病 (DDD) 引起的腰痛是导致残疾和发病的最常见原因之一，尤其是在老年人中。当前腰椎 DDD 管理的研究工作正在转向识别和纠正椎间盘病变，无需任何外部操作。在此，我们对当前有关腰椎 DDD 再生治疗的文献进行了系统回顾。对所有可用年份的文章进行了包括 PubMed、Ovid/MEDLINE、Cochrane 和 Scopus 在内的数据库的电子搜索。研究调查了腰椎 DDD 椎间盘源性疼痛的治疗，包括任何类型的干细胞或骨髓浓缩物作为治疗剂，以及报告基线和随访疼痛以及 Oswestry 残疾指数 (ODI) 评分的研究都被纳入该评价。计算 3 个月、6 个月和 12 个月期间的疼痛和 ODI 评分的变化。共评估了 6 项研究，共 93 名患者。合并样本的平均 (SD) 年龄为 40.0(8.1) 岁，39.5% (32/81) 的患者为女性。3 个月时，38.8% 的患者报告疼痛改善，6 个月时为 40.8%，12 个月时为 44.1%。3 个月、6 个月和 12 个月随访的 ODI 评分平均改善分别计算为 24.0、26.5 和 25.7。再生疗法正越来越多地应用于所有医学领域。对六项单臂研究的回顾揭示了初步结果的潜在积极影响。然而，这些有希望的“初步”结果不应被解释为确定的治疗方法，而应通过进一步的前瞻性研究进行验证。